Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Raised by First Republic Investment Management Inc.

First Republic Investment Management Inc. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 139.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 28,088 shares of the biopharmaceutical company’s stock after acquiring an additional 16,365 shares during the period. First Republic Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $19,349,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of REGN. Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 92.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,694,308 shares of the biopharmaceutical company’s stock worth $1,001,556,000 after purchasing an additional 813,967 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Regeneron Pharmaceuticals by 108.3% in the 2nd quarter. Renaissance Technologies LLC now owns 583,062 shares of the biopharmaceutical company’s stock worth $344,665,000 after purchasing an additional 303,200 shares during the last quarter. FMR LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.9% in the 2nd quarter. FMR LLC now owns 10,176,199 shares of the biopharmaceutical company’s stock valued at $6,015,457,000 after buying an additional 193,175 shares during the period. Great West Life Assurance Co. Can acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $116,414,000. Finally, Pendal Group Ltd boosted its holdings in shares of Regeneron Pharmaceuticals by 5,221.0% in the 2nd quarter. Pendal Group Ltd now owns 158,779 shares of the biopharmaceutical company’s stock valued at $93,859,000 after buying an additional 155,795 shares during the period. Institutional investors own 84.25% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3 %

REGN stock opened at $727.47 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $538.01 and a 52 week high of $779.00. The company has a market capitalization of $79.22 billion, a price-to-earnings ratio of 15.34, a price-to-earnings-growth ratio of 2.17 and a beta of 0.22. The firm’s 50-day moving average is $732.22 and its two-hundred day moving average is $690.27. The company has a current ratio of 5.36, a quick ratio of 4.52 and a debt-to-equity ratio of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported $9.98 EPS for the quarter, topping analysts’ consensus estimates of $8.55 by $1.43. Regeneron Pharmaceuticals had a net margin of 39.17% and a return on equity of 31.16%. The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.79 billion. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. StockNews.com assumed coverage on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Guggenheim decreased their price target on shares of Regeneron Pharmaceuticals from $925.00 to $915.00 and set a “buy” rating for the company in a report on Friday, November 11th. JPMorgan Chase & Co. raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 price target for the company in a report on Friday, January 20th. Truist Financial lifted their price target on shares of Regeneron Pharmaceuticals from $790.00 to $856.00 in a report on Wednesday, November 9th. Finally, Raymond James lowered shares of Regeneron Pharmaceuticals from a “market perform” rating to an “underperform” rating in a report on Wednesday, October 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $786.15.

Insider Buying and Selling

In related news, Director N Anthony Coles sold 5,758 shares of the business’s stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $714.11, for a total value of $4,111,845.38. Following the sale, the director now directly owns 1,093 shares in the company, valued at approximately $780,522.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director N Anthony Coles sold 5,758 shares of the business’s stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $714.11, for a total value of $4,111,845.38. Following the sale, the director now directly owns 1,093 shares in the company, valued at approximately $780,522.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 264 shares of the business’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $730.17, for a total transaction of $192,764.88. Following the completion of the sale, the executive vice president now owns 19,106 shares in the company, valued at $13,950,628.02. The disclosure for this sale can be found here. Insiders have sold 19,212 shares of company stock worth $14,070,511 in the last ninety days. 8.99% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.